OMER 18.26 Omeros Corp $OMER Hit a 52 week high of 19.27 Closing the day 09:45 at 18.26 -0.79 -4.15% With a day low of 18.01 and a total volume of 124,829.
OMER Recent Posts: http://investorshangout.com/Omeros-Corp-OMER-54977/
OMER Omeros Corp Recent Headline News
Omeros (OMER) Catches Eye: Stock Jumps 8.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 7:30AM CST
Omeros Corporation (OMER) was a big mover last session, as the company saw its shares rise almost 9% on the day.
ABAX: 53.80 (+0.30), GWPH: 75.00 (+0.23), OSUR: 9.18 (-0.06), OMER: 19.56 (+0.51)
Omeros ups revenues 9% in Q3
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 10:27AM CST
OMER: 19.56 (+0.51)
Omeros (OMER) CEO Gregory Demopulos on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 10:15PM CST
OMER: 19.56 (+0.51)
Omeros posts 3Q loss
Automated Insights - Mon Nov 10, 5:48PM CST
SEATTLE (AP) _ Omeros Corporation (OMER) on Monday reported a loss of $18.3 million, or 54 cents per share, in its third quarter.
OMER: 19.56 (+0.51)
Omeros beats by $0.05
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 3:19PM CST
OMER: 19.56 (+0.51)
Omeros Corporation Reports Third Quarter 2014 Financial Results
PR Newswire - Mon Nov 10, 3:02PM CST
Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced recent highlights and developments as well as financial results for the third quarter of 2014, which include:
OMER: 19.56 (+0.51)
Notable earnings after Monday’s close
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:35PM CST
HK: 3.05 (+0.03), WWD: 50.99 (+2.29), LLNW: 2.69 (unch), FXEN: 2.73 (+0.01), RMTI: 11.19 (+0.04), CZR: 13.38 (+2.24), EGY: 7.14 (-0.05), ICUI: 83.83 (+2.96), ICEL: 7.64 (+0.11), SAAS: 8.80 (-0.26), DMD: 5.74 (-0.19), NPSP: 28.88 (-0.53), SCLN: 8.49 (+0.25), ATHX: 1.42 (-0.07), CMLS: 3.29 (-0.04), TC: 2.11 (-0.04), ATW: 35.78 (-0.47), CLUB: 6.10 (-0.04), RAX: 42.61 (+0.36), PTLA: 27.47 (+0.22), IPAR: 28.78 (-0.38), ATLS: 36.72 (-0.36), AMBC: 26.12 (+1.31), CUI: 7.84 (-0.05), PDLI: 8.11 (unch), OMER: 19.56 (+0.51), PRAA: 62.66 (+1.01), CARA: 8.30 (-0.18), HALO: 8.91 (+0.09), MODN: 10.36 (-0.10), CALL: 8.55 (+0.03), ASEI: 45.28 (-1.73), HGR: 20.50 (-0.03), ERII: 4.56 (+0.13)
Biotech Watchlist Update: Small-Cap Biotechs Struggle, But Investors Remain Enchanted By Big Pharma's Returns
Life Sciences Report - Seeking Alpha - Fri Nov 07, 8:16AM CST
When the biotechnology market hit a speed bump in early 2014, every stock in the sector was jolted. Large-cap biotech and big pharma have largely recovered, but small- and micro-cap companies haven't yet entirely recouped the losses. The performance...
CERS: 4.18 (-0.02), PCYC: 137.79 (+3.50), CLDX: 14.74 (+0.28), INCY: 72.25 (+1.19), BIND: 9.88 (+0.07), CELG: 108.11 (+0.26), OMER: 19.56 (+0.51), VSTM: 9.26 (+0.06), GILD: 107.20 (-0.81), OGXI: 2.10 (-0.05), ANTH: 1.78 (-0.06), NVAX: 5.18 (-0.11)
Global Cognitive Impairment Therapeutics Pipeline Review 2014 - 53 Drug Profiles from 23 Leading Pharma Companies
M2 - Fri Nov 07, 6:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/jxpc52/cognitive) has announced the addition of the "Cognitive Impairment - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cognitive Impairment, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cognitive Impairment and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - AstraZeneca PLC - Merck & Co., Inc. - Panacea Pharmaceuticals, Inc. - Pfizer Inc. - Teva Pharmaceutical Industries Limited - Shire Plc - Evotec AG - Suven Life Sciences Ltd. - AGY Therapeutics, Inc. - Cardax Pharmaceuticals, Inc. - Siena Biotech S.p.A. - Virogenomics, Inc. - Dart NeuroScience LLC - Omeros Corporation - Intra-Cellular Therapies, Inc. - Heptares Therapeutics Ltd. - Pacific Northwest Biotechnology, LLC - Vicore Pharma AB - Pherin Pharmaceuticals, Inc. - AbbVie Inc. - Saniona AB For more information visit http://www.researchandmarkets.com/research/jxpc52/cognitive
SHPG: 200.80 (-1.41), PFE: 30.49 (+0.17), MRK: 59.26 (-0.11), AZN: 74.22 (+0.02), TEVA: 58.36 (+0.17), ITCI: 15.30 (-0.25), ABBV: 63.71 (-0.14), BMY: 58.67 (-0.05), OMER: 19.56 (+0.51)
Global Thrombotic Thrombocytopenic Purpura Therapeutics Pipeline Review 2014 - 6 Companies & 6 Drug Profiles
M2 - Fri Nov 07, 5:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/thbpxv/thrombotic) has announced the addition of the "Thrombotic Thrombocytopenic Purpura - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Thrombotic Thrombocytopenic Purpura, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thrombotic Thrombocytopenic Purpura and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Ablynx NV - Kaketsuken K.K. - Glenmark Pharmaceuticals Ltd. - Octapharma AG - Archemix Corp. - Omeros Corporation Drug Profiles - plasma (human) - OMS-721 - caplacizumab - Recombinant Enzyme to Target ADAMTS-13 for Thrombotic Thrombocytopenic Purpura - GBR-600 - ARC-15105 For more information visit http://www.researchandmarkets.com/research/thbpxv/thrombotic
OMER: 19.56 (+0.51)
Omeros Announces Positive Data for MASP-2 Inhibitor in Experimental Model of Stroke
PR Newswire - Thu Nov 06, 6:00AM CST
Omeros Corporation (NASDAQ: OMER) today announced positive data using a derivative of OMS721 in a well-established animal model of stroke. OMS721 is the company's lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2). MASP-2 is critical to the function of the lectin pathway, one of the principal components of the complement system, a key part of the immune response. Omeros controls the worldwide rights to MASP-2 inhibition and to all therapeutics targeting MASP-2.
OMER: 19.56 (+0.51)
Global Bipolar Disorder (Manic Depression) Therapeutics Pipeline Review, H2 2014 - 22 Companies & 30 Drug Profiles
M2 - Thu Nov 06, 3:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/6grxbp/bipolar_disorder) has announced the addition of the "Bipolar Disorder (Manic Depression) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bipolar Disorder (Manic Depression), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bipolar Disorder (Manic Depression) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Eli Lilly and Company - Sumitomo Dainippon Pharma Co., Ltd. - Takeda Pharmaceutical Company Limited - Zogenix, Inc. - Richter Gedeon Nyrt. - Pfizer Inc. - Teva Pharmaceutical Industries Limited - Transition Therapeutics Inc. - Intas Pharmaceuticals Ltd. - D-Pharm Ltd. - Omeros Corporation - Intra-Cellular Therapies, Inc. - KemPharm, Inc. - Ascendis Pharma A/S - Otsuka Holdings Co., Ltd. - Reviva Pharmaceuticals Inc. - MarcoPolo Pharmaceuticals SA - Delpor, Inc. - Zysis Limited - Convergence Pharmaceuticals Ltd. - SK Biopharmaceuticals Co., Ltd. Drug Profiles - aripiprazole - quetiapine fumarate ER - ramelteon - ELND-005 - ziprasidone hydrochloride - cariprazine - YKP-3089 - Endoxifen - ITI-007 - DP-VPA - LY-2979165 - risperidone - Drug for Cancer and Neurodegenerative Disease - aripiprazole CR - lurasidone hydrochloride - SKL-PSY - Small Molecule To Antagonize GPR78 for Bipolar Disorder and Schizophrenia - NP-202 - ACP-005 - Small Molecule to Target GPR50 for CNS and Metabolic Disorders - risperidone - paliperidone - CNV-1061436 - PGW-5 - KP-303 - MP-03 - Small Molecules to Antagonize NMDA Receptor and CHRNA7 for CNS - Synthetic Peptides to inhibit IMPase for Bipolar Disorder - BRDK-98958073 - RP-5063 For more information visit http://www.researchandmarkets.com/research/6g...r_disorder
ZGNX: 1.32 (-0.02), PFE: 30.49 (+0.17), AZN: 74.22 (+0.02), TTHI: 6.42 (+0.03), TEVA: 58.36 (+0.17), ITCI: 15.30 (-0.25), LLY: 67.64 (-0.21), OMER: 19.56 (+0.51)
Omeros reports November 10
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 10:53AM CST
OMER: 19.56 (+0.51)
Omeros Corporation to Announce Third Quarter 2014 Financial Results on November 10, 2014
PR Newswire - Tue Nov 04, 6:00AM CST
Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that the company will issue its third quarter 2014 financial results for the period ended September 30, 2014, on Monday, November 10, 2014, after market close. Omeros management will host a conference call and webcast that day at 4:30 p.m. Eastern Time to discuss the financial results.
OMER: 19.56 (+0.51)
Nasdaq stocks posting largest percentage increases
AP - Thu Oct 30, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
IMDZ: 30.35 (+0.41), ABMD: 33.22 (+0.13), BGFV: 13.32 (+0.33), RDCM: 9.15 (-0.15), AMED: 24.99 (+0.04), MRCY: 13.44 (+0.02), OMER: 19.56 (+0.51), ESBF: 19.22 (+0.31), EVOK: 6.80 (-0.06), IQNT: 18.41 (+0.71), KONA: 22.71 (-0.46), TQNT: 22.07 (-0.24), LAKE: 12.46 (-0.26), SAJA: 6.01 (-0.24)
Why Omeros Corporation Stock Saw Big Gains
Sean Williams, The Motley Fool - Motley Fool - Thu Oct 30, 12:47PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Omeros , a biopharmaceutical company...
OMER: 19.56 (+0.51)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 11:47AM CDT
ABMD: 33.22 (+0.13), CALX: 11.15 (-0.16), LOJN: 2.69 (-0.01), ALU: 3.15 (-0.04), CDTI: 2.36 (-0.10), NKA: 5.11 (+0.58), ARAY: 6.99 (-0.03), GLUU: 3.75 (-0.11), PDII: 1.98 (+0.20), OMER: 19.56 (+0.51), ESBF: 19.22 (+0.31), CRNT: 1.18 (+0.08), CBDE: 0.85 (-0.11), PRXL: 56.09 (+1.23), BWEN: 6.63 (+0.18), ALDX: 7.47 (-0.04), BBSI: 22.52 (-0.58), LAKE: 12.46 (-0.26), OPHC: 0.95 (+0.01), WTW: 26.58 (+0.68)
Omidria(TM) Granted Pass-Through Reimbursement Status from CMS
PR Newswire - Thu Oct 30, 6:00AM CDT
Omeros Corporation (NASDAQ: OMER) announced today that it has received transitional pass-through status for its lead product Omidria(TM) (phenylephrine and ketorolac injection) 1%/0.3% from the Center for Medicare & Medicaid Services (CMS), the federal agency that administers the Medicare program. Approved earlier this year by the U.S. Food and Drug Administration (FDA) for use during cataract surgery or intraocular lens replacement (ILR), Omidria is the only FDA-approved product for intraocular administration that prevents intraoperative miosis (pupil constriction) and reduces postoperative pain, providing consistent and predictable management of these problems for ophthalmic surgeons and their patients. A large and growing market, cataract and other ILR procedures are among the most common surgical procedures performed in the U.S. with approximately four million expected in 2015.
OMER: 19.56 (+0.51)
Omeros Falls as Enrollment for OMS824 Study is Suspended - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 23, 3:10PM CDT
Omeros Corporation (OMER) suffered a pipeline setback with the company announcing the suspension of enrollment in a phase II study evaluating OMS824.
MDVN: 107.04 (-0.25), AUXL: 32.51 (-0.09), LGND: 57.15 (+0.25), OMER: 19.56 (+0.51)
OMER Recent Posts: http://investorshangout.com/Omeros-Corp-OMER-54977/
OMER Omeros Corp Recent Headline News
Omeros (OMER) Catches Eye: Stock Jumps 8.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 7:30AM CST
Omeros Corporation (OMER) was a big mover last session, as the company saw its shares rise almost 9% on the day.
ABAX: 53.80 (+0.30), GWPH: 75.00 (+0.23), OSUR: 9.18 (-0.06), OMER: 19.56 (+0.51)
Omeros ups revenues 9% in Q3
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 10:27AM CST
OMER: 19.56 (+0.51)
Omeros (OMER) CEO Gregory Demopulos on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 10:15PM CST
OMER: 19.56 (+0.51)
Omeros posts 3Q loss
Automated Insights - Mon Nov 10, 5:48PM CST
SEATTLE (AP) _ Omeros Corporation (OMER) on Monday reported a loss of $18.3 million, or 54 cents per share, in its third quarter.
OMER: 19.56 (+0.51)
Omeros beats by $0.05
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 3:19PM CST
OMER: 19.56 (+0.51)
Omeros Corporation Reports Third Quarter 2014 Financial Results
PR Newswire - Mon Nov 10, 3:02PM CST
Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced recent highlights and developments as well as financial results for the third quarter of 2014, which include:
OMER: 19.56 (+0.51)
Notable earnings after Monday’s close
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:35PM CST
HK: 3.05 (+0.03), WWD: 50.99 (+2.29), LLNW: 2.69 (unch), FXEN: 2.73 (+0.01), RMTI: 11.19 (+0.04), CZR: 13.38 (+2.24), EGY: 7.14 (-0.05), ICUI: 83.83 (+2.96), ICEL: 7.64 (+0.11), SAAS: 8.80 (-0.26), DMD: 5.74 (-0.19), NPSP: 28.88 (-0.53), SCLN: 8.49 (+0.25), ATHX: 1.42 (-0.07), CMLS: 3.29 (-0.04), TC: 2.11 (-0.04), ATW: 35.78 (-0.47), CLUB: 6.10 (-0.04), RAX: 42.61 (+0.36), PTLA: 27.47 (+0.22), IPAR: 28.78 (-0.38), ATLS: 36.72 (-0.36), AMBC: 26.12 (+1.31), CUI: 7.84 (-0.05), PDLI: 8.11 (unch), OMER: 19.56 (+0.51), PRAA: 62.66 (+1.01), CARA: 8.30 (-0.18), HALO: 8.91 (+0.09), MODN: 10.36 (-0.10), CALL: 8.55 (+0.03), ASEI: 45.28 (-1.73), HGR: 20.50 (-0.03), ERII: 4.56 (+0.13)
Biotech Watchlist Update: Small-Cap Biotechs Struggle, But Investors Remain Enchanted By Big Pharma's Returns
Life Sciences Report - Seeking Alpha - Fri Nov 07, 8:16AM CST
When the biotechnology market hit a speed bump in early 2014, every stock in the sector was jolted. Large-cap biotech and big pharma have largely recovered, but small- and micro-cap companies haven't yet entirely recouped the losses. The performance...
CERS: 4.18 (-0.02), PCYC: 137.79 (+3.50), CLDX: 14.74 (+0.28), INCY: 72.25 (+1.19), BIND: 9.88 (+0.07), CELG: 108.11 (+0.26), OMER: 19.56 (+0.51), VSTM: 9.26 (+0.06), GILD: 107.20 (-0.81), OGXI: 2.10 (-0.05), ANTH: 1.78 (-0.06), NVAX: 5.18 (-0.11)
Global Cognitive Impairment Therapeutics Pipeline Review 2014 - 53 Drug Profiles from 23 Leading Pharma Companies
M2 - Fri Nov 07, 6:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/jxpc52/cognitive) has announced the addition of the "Cognitive Impairment - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cognitive Impairment, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cognitive Impairment and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - AstraZeneca PLC - Merck & Co., Inc. - Panacea Pharmaceuticals, Inc. - Pfizer Inc. - Teva Pharmaceutical Industries Limited - Shire Plc - Evotec AG - Suven Life Sciences Ltd. - AGY Therapeutics, Inc. - Cardax Pharmaceuticals, Inc. - Siena Biotech S.p.A. - Virogenomics, Inc. - Dart NeuroScience LLC - Omeros Corporation - Intra-Cellular Therapies, Inc. - Heptares Therapeutics Ltd. - Pacific Northwest Biotechnology, LLC - Vicore Pharma AB - Pherin Pharmaceuticals, Inc. - AbbVie Inc. - Saniona AB For more information visit http://www.researchandmarkets.com/research/jxpc52/cognitive
SHPG: 200.80 (-1.41), PFE: 30.49 (+0.17), MRK: 59.26 (-0.11), AZN: 74.22 (+0.02), TEVA: 58.36 (+0.17), ITCI: 15.30 (-0.25), ABBV: 63.71 (-0.14), BMY: 58.67 (-0.05), OMER: 19.56 (+0.51)
Global Thrombotic Thrombocytopenic Purpura Therapeutics Pipeline Review 2014 - 6 Companies & 6 Drug Profiles
M2 - Fri Nov 07, 5:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/thbpxv/thrombotic) has announced the addition of the "Thrombotic Thrombocytopenic Purpura - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Thrombotic Thrombocytopenic Purpura, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thrombotic Thrombocytopenic Purpura and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Ablynx NV - Kaketsuken K.K. - Glenmark Pharmaceuticals Ltd. - Octapharma AG - Archemix Corp. - Omeros Corporation Drug Profiles - plasma (human) - OMS-721 - caplacizumab - Recombinant Enzyme to Target ADAMTS-13 for Thrombotic Thrombocytopenic Purpura - GBR-600 - ARC-15105 For more information visit http://www.researchandmarkets.com/research/thbpxv/thrombotic
OMER: 19.56 (+0.51)
Omeros Announces Positive Data for MASP-2 Inhibitor in Experimental Model of Stroke
PR Newswire - Thu Nov 06, 6:00AM CST
Omeros Corporation (NASDAQ: OMER) today announced positive data using a derivative of OMS721 in a well-established animal model of stroke. OMS721 is the company's lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2). MASP-2 is critical to the function of the lectin pathway, one of the principal components of the complement system, a key part of the immune response. Omeros controls the worldwide rights to MASP-2 inhibition and to all therapeutics targeting MASP-2.
OMER: 19.56 (+0.51)
Global Bipolar Disorder (Manic Depression) Therapeutics Pipeline Review, H2 2014 - 22 Companies & 30 Drug Profiles
M2 - Thu Nov 06, 3:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/6grxbp/bipolar_disorder) has announced the addition of the "Bipolar Disorder (Manic Depression) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bipolar Disorder (Manic Depression), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bipolar Disorder (Manic Depression) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Eli Lilly and Company - Sumitomo Dainippon Pharma Co., Ltd. - Takeda Pharmaceutical Company Limited - Zogenix, Inc. - Richter Gedeon Nyrt. - Pfizer Inc. - Teva Pharmaceutical Industries Limited - Transition Therapeutics Inc. - Intas Pharmaceuticals Ltd. - D-Pharm Ltd. - Omeros Corporation - Intra-Cellular Therapies, Inc. - KemPharm, Inc. - Ascendis Pharma A/S - Otsuka Holdings Co., Ltd. - Reviva Pharmaceuticals Inc. - MarcoPolo Pharmaceuticals SA - Delpor, Inc. - Zysis Limited - Convergence Pharmaceuticals Ltd. - SK Biopharmaceuticals Co., Ltd. Drug Profiles - aripiprazole - quetiapine fumarate ER - ramelteon - ELND-005 - ziprasidone hydrochloride - cariprazine - YKP-3089 - Endoxifen - ITI-007 - DP-VPA - LY-2979165 - risperidone - Drug for Cancer and Neurodegenerative Disease - aripiprazole CR - lurasidone hydrochloride - SKL-PSY - Small Molecule To Antagonize GPR78 for Bipolar Disorder and Schizophrenia - NP-202 - ACP-005 - Small Molecule to Target GPR50 for CNS and Metabolic Disorders - risperidone - paliperidone - CNV-1061436 - PGW-5 - KP-303 - MP-03 - Small Molecules to Antagonize NMDA Receptor and CHRNA7 for CNS - Synthetic Peptides to inhibit IMPase for Bipolar Disorder - BRDK-98958073 - RP-5063 For more information visit http://www.researchandmarkets.com/research/6g...r_disorder
ZGNX: 1.32 (-0.02), PFE: 30.49 (+0.17), AZN: 74.22 (+0.02), TTHI: 6.42 (+0.03), TEVA: 58.36 (+0.17), ITCI: 15.30 (-0.25), LLY: 67.64 (-0.21), OMER: 19.56 (+0.51)
Omeros reports November 10
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 10:53AM CST
OMER: 19.56 (+0.51)
Omeros Corporation to Announce Third Quarter 2014 Financial Results on November 10, 2014
PR Newswire - Tue Nov 04, 6:00AM CST
Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that the company will issue its third quarter 2014 financial results for the period ended September 30, 2014, on Monday, November 10, 2014, after market close. Omeros management will host a conference call and webcast that day at 4:30 p.m. Eastern Time to discuss the financial results.
OMER: 19.56 (+0.51)
Nasdaq stocks posting largest percentage increases
AP - Thu Oct 30, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
IMDZ: 30.35 (+0.41), ABMD: 33.22 (+0.13), BGFV: 13.32 (+0.33), RDCM: 9.15 (-0.15), AMED: 24.99 (+0.04), MRCY: 13.44 (+0.02), OMER: 19.56 (+0.51), ESBF: 19.22 (+0.31), EVOK: 6.80 (-0.06), IQNT: 18.41 (+0.71), KONA: 22.71 (-0.46), TQNT: 22.07 (-0.24), LAKE: 12.46 (-0.26), SAJA: 6.01 (-0.24)
Why Omeros Corporation Stock Saw Big Gains
Sean Williams, The Motley Fool - Motley Fool - Thu Oct 30, 12:47PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Omeros , a biopharmaceutical company...
OMER: 19.56 (+0.51)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 11:47AM CDT
ABMD: 33.22 (+0.13), CALX: 11.15 (-0.16), LOJN: 2.69 (-0.01), ALU: 3.15 (-0.04), CDTI: 2.36 (-0.10), NKA: 5.11 (+0.58), ARAY: 6.99 (-0.03), GLUU: 3.75 (-0.11), PDII: 1.98 (+0.20), OMER: 19.56 (+0.51), ESBF: 19.22 (+0.31), CRNT: 1.18 (+0.08), CBDE: 0.85 (-0.11), PRXL: 56.09 (+1.23), BWEN: 6.63 (+0.18), ALDX: 7.47 (-0.04), BBSI: 22.52 (-0.58), LAKE: 12.46 (-0.26), OPHC: 0.95 (+0.01), WTW: 26.58 (+0.68)
Omidria(TM) Granted Pass-Through Reimbursement Status from CMS
PR Newswire - Thu Oct 30, 6:00AM CDT
Omeros Corporation (NASDAQ: OMER) announced today that it has received transitional pass-through status for its lead product Omidria(TM) (phenylephrine and ketorolac injection) 1%/0.3% from the Center for Medicare & Medicaid Services (CMS), the federal agency that administers the Medicare program. Approved earlier this year by the U.S. Food and Drug Administration (FDA) for use during cataract surgery or intraocular lens replacement (ILR), Omidria is the only FDA-approved product for intraocular administration that prevents intraoperative miosis (pupil constriction) and reduces postoperative pain, providing consistent and predictable management of these problems for ophthalmic surgeons and their patients. A large and growing market, cataract and other ILR procedures are among the most common surgical procedures performed in the U.S. with approximately four million expected in 2015.
OMER: 19.56 (+0.51)
Omeros Falls as Enrollment for OMS824 Study is Suspended - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 23, 3:10PM CDT
Omeros Corporation (OMER) suffered a pipeline setback with the company announcing the suspension of enrollment in a phase II study evaluating OMS824.
MDVN: 107.04 (-0.25), AUXL: 32.51 (-0.09), LGND: 57.15 (+0.25), OMER: 19.56 (+0.51)
